CS Diagnostics Corporation (QB) (CSDX)

Are these combined financials? It didn’t look like they were. No mention of other companies.

Are these combined financials? It didn’t look like they were. No mention of other companies.

$CSDX CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH

https://www.globenewswire.com/news-release/2026/02/11/3236439/0/en/CS-Group-OTCQB-CSDX-Appoints-Shah-Teelani-Associates-a-Dubai-Based-PCAOB-Auditor-to-Consolidate-All-2025-Financial-Statements-for-CSDX-CS-Interpharm-GT-LLC-and-CS-Diagnostics-Pharm.html

CHEYENNE, Wyo., Feb. 11, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX) (“CS Group” or the “Company”), a medical technology and hygiene solutions company, today announced the appointment of Shah Teelani & Associates, a Dubai-based Public Company Accounting Oversight Board (PCAOB) registered audit firm, to consolidate and audit the Group 2025 financial statements.

Under the engagement, Shah Teelani & Associates will oversee the consolidation and audit of financial statements for:

CS Diagnostics Corp. (OTCQB: CSDX)
CS Interpharm GT LLC
CS Diagnostics Pharma GmbH

The engagement reflects the Group’s continued commitment to strengthening financial governance, regulatory compliance, and transparency as it advances its international expansion strategy across the United States, GCC region, and Europe.

Management stated that appointing a PCAOB-registered audit firm is a significant step in aligning the Group’s financial reporting structure with U.S. public company standards while integrating its growing international companies under a unified reporting framework. The consolidated audit will support enhanced financial clarity, streamlined reporting processes, and strengthened investor confidence.

The 2025 consolidated financial review will encompass operations related to the MEDUSA hygiene and disinfectant platform, international distribution expansion.

“Engaging Shah Teelani & Associates as our PCAOB-registered auditor represents an important milestone in CS Group’s evolution as a publicly traded company,” said Mohammad Essayed, Group Chief Financial Officer. “As we scale operations across multiple regions, it is essential that our financial reporting structure reflects institutional-grade standards, transparency, and regulatory compliance. This appointment strengthens our governance foundation and supports our long-term growth strategy.”

The Group continues to focus on expanding its manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its broader global growth roadmap.

fasten your seatbelt folks. double multiple hi channel .

$CSDX "has been contracted to manufacture the MEDUSA SDP disinfectant wet wipes product line, while Gulf Centre Group Factory will produce bulk liquid hygiene and disinfectant formulations, including 500ml bottles and 5-liter commercial formats. "

$CSDX announced the confirmation of strategic manufacturing partnerships with Emirate Wet Wipes LLC that accelerate the Company’s transition into full commercial production ahead of the global launch of MEDUSA SDP, its next-generation medical-grade wet wipes and liquid disinfectant hygiene products designed for healthcare, institutional, and consumer markets.

Is that lady AI? Pretty impressive

$CSDX Latest News : CS Group Secures Strategic Manufacturing Partnerships, Accelerating Global Commercial Launch of MEDUSA SDP Hygiene Products https://finance.yahoo.com/news/cs-group-otcqb-csdx-secures-134900592.html

$CSDX The Low Float Diagnostics Play Eyeing Nasdaq

$CSDX CS Diagnostics Taps UAE Giants for Global MEDUSA Hygiene Launch

https://briefglance.com/articles/cs-diagnostics-taps-uae-giants-for-global-medusa-hygiene-launch

$CSDX CS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDP

https://www.globenewswire.com/news-release/2026/01/21/3223001/0/en/CS-Group-OTCQB-CSDX-Announces-Multi-Channel-Sales-Model-Global-Logistics-Partners-and-Sustainable-Innovation-Roadmap-for-MEDUSA-SDP.html

CHEYENNE, Wyo., Jan. 21, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX) today detailed its multi-channel sales strategy, global logistics partnerships, and sustainability roadmap supporting the commercial rollout of MEDUSA SDP.

The Company plans to distribute MEDUSA SDP through a diversified sales model designed to serve both institutional and consumer demand.

B2B distribution channels include:

Hospitals and healthcare facilities
Gyms and wellness centers
Schools and educational institutions
Corporate and industrial clients

B2C channels include:

Physical retail Stores shelves, in UAE and Germany.
Online marketplaces such as Amazon, Noon, and leading German e-commerce platforms
Direct-to-consumer sales via the official MEDUSA e-commerce website

To support efficient global fulfillment, DHL has been selected for bulk and institutional shipments, while FedEx will manage retail and consumer-focused deliveries.

Looking ahead, the Company expects to begin regulatory approval processes for a bio-degradable, dissolving MEDUSA SDP wet wipes line, representing a breakthrough advancement in sustainable hygiene solutions and reinforcing CSDX’s long-term environmental strategy.

“CS Group is focused on disciplined execution, strategic partnerships, and scalable growth,” Management stated. “MEDUSA SDP demonstrates how we translate innovation into commercially viable, globally relevant products while advancing sustainability.”

$CSDX - " Company profile verified and Management Certificate uploaded on OTC Markets.

News coming up🪄"

Company profile verified and Management Certificate uploaded on OTC Markets.

News coming up🪄$CSDX pic.twitter.com/Og7OQxrDA2— CS Diagnostics Corp. (@CSDX_CSDCorp) January 15, 2026

$CSDX - " 🚀 MEDUSA has arrived. Production is moving, first inventory expected Feb 2026. Sales kick off in UAE & Germany simultaneously, with additional markets to follow. Wet Wipes. Bottles. Take a peek at our wet wipes 📷👀>#MEDUSA #2026 "

🚀 MEDUSA has arrived. Production is moving, first inventory expected Feb 2026. Sales kick off in UAE & Germany simultaneously, with additional markets to follow. Wet Wipes. Bottles. Take a peek at our wet wipes 👀 Big momentum ahead. 🔥 $CSDX #MEDUSA #2026 pic.twitter.com/BmaqD4mCaN— CS Diagnostics Corp. (@CSDX_CSDCorp) January 5, 2026

Looks like the CEO received another award

need more clarity $CSDX



imo -

Based on the most recent filing, Medusa has not been submitted to EPA yet and hydrogel needs more testing. The year ahead has no mention of Medusa only potential hydrogel approval. We will need to see consolidated financials in Feb to see the combined company.

what's the latest on this company/stock ??

$CSDX Shareholder Update 🚀 CSDX Shareholder Update

The CSDX team is pushing forward with strong momentum as we advance our Reg D 506(c) offering. Our marketing and investor outreach efforts are in full swing — and the results are exciting.

✨ We’ve already connected with 5,250+ family offices, fund… pic.twitter.com/d3A3QReVdC— CS Diagnostics Corp. (@CSDX_CSDCorp) November 24, 2025

$CSDX - "🚀 CSDX Shareholder Update

The CSDX team is pushing forward with strong momentum as we advance our Reg D 506(c) offering. Our marketing and investor outreach efforts are in full swing — and the results are exciting.

✨ We’ve already connected with 5,250+ family offices, fund managers, and top-tier investment firms through our targeted campaign.

📞 31 investor calls completed
📝 47 applications processed
📂 22 additional investment applications currently under documentation review and updates

We’re steadily expanding our reach, building high-value investment relationships, and positioning CSDX for its next major phase of growth.

More updates coming soon — stay tuned! "

🚀 CSDX Shareholder Update

The CSDX team is pushing forward with strong momentum as we advance our Reg D 506(c) offering. Our marketing and investor outreach efforts are in full swing — and the results are exciting.

✨ We’ve already connected with 5,250+ family offices, fund… pic.twitter.com/d3A3QReVdC— CS Diagnostics Corp. (@CSDX_CSDCorp) November 24, 2025

CSDX in play early noise for the crowds to come. amen!
From 52 weeks range. then now hmm. juicy ?
0.036 - 3.50

Why this one on BIOTECH ? choice of thinking ?

Transforming healthcare through innovation and shaping the future of medical technology

hmmm, emphasizing

$CSDX - "🚀 📷$CSDX!
Our latest 10-Q for the period ended September 30th 2025 has been filed.
Snapshot shows powerful progress:

• 📈 189% revenue growth in the most recent period
• 🔧 Liabilities remain extremely low
• 🧭 Continued improvement in retained earnings

We’re building, scaling, and delivering—one milestone at a time. Onward and upward! Towards our consolidation of our Annual Reports 2025 🚀📷✨"

🚀 🚀 Big Momentum at $CSDX!

Our latest 10-Q for the period ended September 30th 2025 has been filed.
Snapshot shows powerful progress:

• 📈 189% revenue growth in the most recent period
• 🔧 Liabilities remain extremely low
• 🧭 Continued improvement in retained earnings… pic.twitter.com/6wsiZI0s81— CS Diagnostics Corp. (@CSDX_CSDCorp) November 17, 2025

AI Overview


+5
Converting Class B or preferred shares to common stock allows shareholders to gain voting rights and benefit from potential capital appreciation as the company grows. This conversion can simplify ownership structures, align shareholder interests with founders, and prepare them for liquidity events like an IPO or acquisition. However, it means giving up the protective features of preferred stock, such as liquidation preference and priority in dividends.
Benefits of converting to common shares
Gaining voting rights: Common shareholders typically have a say in corporate governance through voting on important decisions.
Accessing capital appreciation: Converting allows shareholders to participate in the company's potential growth and profit from the increase in the stock's value above the purchase price.
Simplifying ownership: Conversion, especially during events like an IPO, can result in a single, easier-to-evaluate share class for public markets.
Aligning interests: It can eliminate conflicts by ensuring that investors and founders benefit equally from future milestones and growth.
Preparing for liquidity events: Automatic conversion ensures that preferred shareholders are ready to participate in events like acquisitions or going public.
Potential drawbacks to consider
Loss of preferred rights: Converting means giving up the benefits of preferred stock, such as priority for dividends and liquidation preference (being paid before common stockholders in case of liquidation).
Risk and volatility: Common stock is subject to market fluctuations and carries a higher risk compared to preferred stock.
Potential tax implications: Converting preferred stock to common stock may generate taxable dividend income for shareholders, depending on the structure and specific circumstances

$CSDX CS Diagnostics Corp. REG D 506 (c) Offering
We are excited to announce our Regulation D (REG D 506 (C)) offering – A defining moment in our ceaseless pursuit of innovation in diagnostics and healthcare solutions. https://csdcorp.us/regd/

$CSDX News Pending ?

In a further commitment to transparency and governance, CSDX expects to become a fully Securities and Exchange Commission (SEC)-reporting company by the end of September 2025. The Company will also take immediate steps to consolidate the financials of its group of companies, providing stakeholders with a clearer, more unified view of its robust performance.

$CSDX CSDX's CS-Protect Hydrogel is advancing rapidly toward market readiness. The Company's application with the U.S. Food and Drug Administration (FDA) is actively under review, with anticipation building for formal authorization. In a bold move to secure global intellectual property protection, CSDX has simultaneously initiated patent filings for CS-Protect Hydrogel in the USA, Europe, the UAE, and six additional strategic countries. This proactive strategy ensures the product is primed for swift commercialization upon FDA approval, positioning CSDX at the forefront of cutting-edge hydrogel technology.

Chart looks good, liquidity train needs to keep chugging along https://www.barchart.com/stocks/quotes/CSDX/overview

EOY .50pps ???

can we break over .19 or what? LETS GO!

We are over .1 Now it would be great for a bump to .25 and maybe get some real momentum and get to .50 soon.

I'm waiting on .04

can we just push this up to .1 to get a little momentum behind it?

print

https://www.stockscores.com/chart.asp?TickerSymbol=csdx&TimeRange=180&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=WMA&movAvg1=20&avgType2=EMA&movAvg2=60&Indicator1=MACD&Indicator2=None&Indicator3=SStoch&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

They are masters at underdelivering

https://www.stockscores.com/chart.asp?TickerSymbol=csdx&TimeRange=180&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=WMA&movAvg1=20&avgType2=EMA&movAvg2=60&Indicator1=MACD&Indicator2=None&Indicator3=SStoch&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

https://www.stockscores.com/chart.asp?TickerSymbol=csdx&TimeRange=180&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=WMA&movAvg1=20&avgType2=EMA&movAvg2=60&Indicator1=MACD&Indicator2=None&Indicator3=SStoch&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

maybe they were talking about first week of July 2026 for the F10 and reg D

Weren't we supposed to get some kind of filing last week?

$CSDX CS Group Announces Strategic MOU Between CS Interpharm and Gulf Center Group for Customized Manufacturing Collaboration

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cs-group-announces-strategic-mou-between-cs-interpharm-and-gulf-cente-1044815

CHEYENNE, WY AND NEUSS, GERMANY / ACCESS Newswire / July 1, 2025 / CS Group announced that its regional subsidiary, CS Interpharm General Trading CO. LLC has signed a Memorandum of Understanding (MOU) and Non-Disclosure Agreement (NDA) with Gulf Center Group, a leading UAE-based manufacturer of plastic packaging and hygiene-related chemicals.

Under this agreement, Gulf Center Group will provide end-to-end manufacturing support for MEDUSA including customized bottle design, filling, and production that are fully aligned with the MEDUSA brand's identity and quality standards. All production will be carried out exclusively for CS Interpharm General Trading CO. LLC, supporting the growth and expansion of its proprietary product MEDUSA and its broader product line.

Thomas Fahrhoefer, Chairman of the Group., added:

"This partnership represents a key step toward enhancing our product line and securing reliable, high-quality manufacturing support from a reputable UAE-based partner."

Mohammad EsSayed, Group Chief Finance Officer., mentioned:

"A major step forward in strengthening our supply chain and production capabilities within the UAE region supporting our mission to deliver quality and efficiency in the healthcare and hygiene sectors."

$CSDX Small Cap Virtual Investor Conference: Now Available for Online Viewing

https://www.globenewswire.com/news-release/2025/06/27/3106554/0/en/Small-Cap-Virtual-Investor-Conference-Now-Available-for-Online-Viewing.html

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Small Cap Virtual Investor Conference, held June 26th are now available for online viewing.

REGISTER AND VIEW PRESENTATIONS

The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section.

Select companies are accepting 1x1 management meeting requests through July 1st.

$CSDX Exclusive Investor Invitation – Discover the Future of Healthcare Innovation
📅 Thursday, June 26 | 🕐 12:30 PM EDT | 🌍 8:30 PM Dubai | 🇩🇪 6:30 PM Berlin
Join CS Diagnostics Corp. LIVE at the Small Cap Growth Virtual Investor Conference

🔬 Backed by Over 25 Years of International Healthcare Expertise.
📈 Publicly Listed on OTCQB – and Poised for Major Growth.
🏥 Trusted by World-Class Hospital Networks and Global Sports Giants.

At CS Diagnostics Corp., we’re not just another healthcare company—we are reshaping the diagnostics landscape. With over two decades of hands-on experience in global medical supply and diagnostics, we have earned the trust of industry leaders across both medicine and professional sports.
Now, we’re entering our next phase of scalable, international growth—and we want you to be part of it.
🎯 Why Should You Join This Live Event?
• Be the first to hear about our latest milestones and growth strategy
• Learn why top-tier hospitals and elite sports organizations rely on our solutions
• Discover how your investment could be part of a high-impact, high-return journey
• Connect directly with the team behind a publicly listed OTCQB healthcare innovator

🔗 Register now to secure your spot and be part of our success story:
[https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/4998796/cs-diagnostics-corp-otcqb-csdx ]

They are presenting on June 26, and the website seems to be working.
https://www.otcmarkets.com/stock/CSDX/news/CS-Diagnostics-Corp-to-Present-at-the-Small-Cap-Growth-Virtual-Investor-Conference-June-26th?id=483761

Is their website down?

$CSDX Need news here..

" "MEDUSA requires reduced application frequency in high-traffic environments delivering cost and labour savings. With regulatory approvals progressing and a clear path to commercialization, we are confident that MEDUSA can capture meaningful market share while delivering value to our partners and end-users."
https://finance.yahoo.com/news/cs-group-announces-valuation-medusa-140000101.html

$CSDX Short interest tracker https://fintel.io/ss/us/csdx

$CSDX Daily to weekly View

$CSDX Big bounce coming.. DD
https://stockta.com/cgi-bin/analysis.pl?symb=CSDX&mode=stock

$CSDX Unrivalled Protection For Every Environment, Every Day ?

https://medusa-sdp.com/en/